Dalaba Maxwell Ayindenaba, Manyeh Alfred Kwesi, Immurana Mustapha, Ayanore Martin Amogre, Agorinya Isaiah, Akazili James, Akweongo Patricia, Quao Benedict Okoe
University of Health and Allied Sciences, Ho, Ghana.
School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.
SAGE Open Med. 2024 Nov 8;12:20503121241281424. doi: 10.1177/20503121241281424. eCollection 2024.
Despite the known detrimental socio-economic consequences of leprosy morbidity, disability and social exclusion at the household level, research investigating the precise economic burden of leprosy remains scarce. This study aims to address this gap by examining the socio-economic burden of leprosy in Ho municipality in the Volta Region of Ghana.
This was a cross-sectional cost of illness study, and quantitative data were collected from leprosy patients between October and December 2023. Data collected included socio-demographic characteristics, direct and indirect costs related to treatment of leprosy from the patient's perspective. Stata version 14 was used for the analysis.
A total of 35 respondents participated in the study, comprising 51.43% females and 48.57% males. All respondents (100%) reported having a valid National Health Insurance Scheme membership. The average total cost of leprosy treatment per patient, encompassing both direct and indirect expenses, was US$361.54 (SD ± 286.87). Disaggregating this cost further revealed a medical cost of US$44.30, a non-medical cost of US$47.07 and an indirect cost of US$290.16. The estimated annual household income of respondents was US$446.4 and 60% of respondents incurred expenditure that was more than 10% of their annual income and were deemed to have experienced catastrophic payment. Patients with sequelae incurred additional costs of US$46 (range: US$8.3-US$166.7) per case.
The costs of treating leprosy were considerably high leading to catastrophic health payments. This highlights the need for an all-encompassing strategy that addresses medical, non-medical and indirect costs. Implementing targeted support programs and ensuring medication affordability are key steps towards mitigating the economic susceptibility of leprosy patients and facilitating successful treatment outcomes.
尽管已知麻风病的发病、残疾和家庭层面的社会排斥会带来有害的社会经济后果,但调查麻风病确切经济负担的研究仍然很少。本研究旨在通过考察加纳沃尔特地区霍市麻风病的社会经济负担来填补这一空白。
这是一项横断面疾病成本研究,于2023年10月至12月收集了麻风病患者的定量数据。收集的数据包括社会人口学特征、从患者角度来看与麻风病治疗相关的直接和间接成本。使用Stata 14版本进行分析。
共有35名受访者参与了该研究,其中女性占51.43%,男性占48.57%。所有受访者(100%)报告拥有有效的国家健康保险计划会员资格。每位患者麻风病治疗的平均总成本,包括直接和间接费用,为361.54美元(标准差±286.87)。进一步细分该成本显示,医疗成本为44.30美元,非医疗成本为47.07美元,间接成本为290.16美元。受访者的估计家庭年收入为446.4美元,60%的受访者支出超过其年收入的10%,被视为经历了灾难性支付。有后遗症的患者每例额外花费46美元(范围:8.3美元至166.7美元)。
治疗麻风病的成本相当高,导致灾难性医疗支出。这凸显了需要一项全面战略来解决医疗、非医疗和间接成本问题。实施有针对性的支持计划并确保药物可负担性是减轻麻风病患者经济易感性并促进成功治疗结果的关键步骤。